









Markets
/
Stocks
/
nasdaq-imnn
/

Imunon Inc

IMNN

3.270USD

+0.200+6.51%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

10.89MMarket Cap

LossP/E TTM



Imunon Inc

3.270

+0.200+6.51%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Imunon Inc

Currency: USD Updated: 2026-02-06

Key Insights

Imunon Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 116 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 60.90.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Imunon Inc's Score

Industry at a Glance

Industry Ranking

116 / 392

Overall Ranking

250 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Imunon Inc Highlights

StrengthsRisks

Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The Company is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.

Undervalued

The company’s latest PE is -0.42, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 162.10K shares, decreasing 44.83% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 37.05K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.97.

Analyst Rating

Based on 4 analysts

Buy

Current Rating

60.902

Target Price

+1883.78%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Imunon Inc is 6.70, ranking 225 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.70

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.02

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.69

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Imunon Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Imunon Inc is 8.45, ranking 43 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.42, which is -96.77% below the recent high of -0.01 and -70.66% above the recent low of -0.71.

Score

Industry at a Glance

Previous score

8.45

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 116/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Imunon Inc is 7.50, ranking 284 out of 392 in the Biotechnology & Medical Research industry. The average price target is 45.00, with a high of 182.61 and a low of 21.00.

Score

Industry at a Glance

Previous score

7.50

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 4 analysts

Buy

Current Rating

60.902

Target Price

+1883.78%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Imunon Inc

IMNN

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Imunon Inc is 6.96, ranking 131 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 3.83 and the support level at 2.87, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.54

Change

0.42

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.054

Sell

RSI(14)

42.118

Neutral

STOCH(KDJ)(9,3,3)

17.010

Neutral

ATR(14)

0.216

High Vlolatility

CCI(14)

-69.432

Neutral

Williams %R

72.109

Sell

TRIX(12,20)

-0.608

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

3.164

Buy

MA10

3.321

Sell

MA20

3.452

Sell

MA50

3.689

Sell

MA100

4.190

Sell

MA200

7.300

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Imunon Inc is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 5.28%, representing a quarter-over-quarter decrease of 34.48%. The largest institutional shareholder is The Vanguard, holding a total of 37.05K shares, representing 1.21% of shares outstanding, with 261.53% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

DRW Securities, LLC

55.03K

The Vanguard Group, Inc.

Star Investors

23.30K

+59.55%

Riverview Capital Advisers, LLC

34.36K

+3726.73%

Geode Capital Management, L.L.C.

19.81K

+78.63%

Tardugno (Michael H)

5.65K

+6.60%

Fritz (Frederick J)

4.54K

+402.99%

BlackRock Institutional Trust Company, N.A.

4.46K

Morgan Stanley Smith Barney LLC

4.43K

+10695.12%

Braun (Donald P)

4.31K

+119.57%

Le (Goff Corinne)

4.06K

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Imunon Inc is 2.90, ranking 187 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 2.06. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.